Browse NR5A2

Summary
SymbolNR5A2
Namenuclear receptor subfamily 5, group A, member 2
Aliases FTZ-F1beta; hB1F; FTZ-F1; hB1F-2; B1F2; liver receptor homolog-1; FTF; B1F; CPF; LRH1; CYP7A promoter-bindin ......
Chromosomal Location1q32.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF00104 Ligand-binding domain of nuclear hormone receptor
PF00105 Zinc finger
Function

Nuclear receptor that acts as a key metabolic sensor by regulating the expression of genes involved in bile acid synthesis, cholesterol homeostasis and triglyceride synthesis. Together with the oxysterol receptors NR1H3/LXR-alpha and NR1H2/LXR-beta, acts as an essential transcriptional regulator of lipid metabolism. Plays an anti-inflammatory role during the hepatic acute phase response by acting as a corepressor: inhibits the hepatic acute phase response by preventing dissociation of the N-Cor corepressor complex (PubMed:20159957). Binds to the sequence element 5'-AACGACCGACCTTGAG-3' of the enhancer II of hepatitis B virus genes, a critical cis-element of their expression and regulation. May be responsible for the liver-specific activity of enhancer II, probably in combination with other hepatocyte transcription factors. Key regulator of cholesterol 7-alpha-hydroxylase gene (CYP7A) expression in liver. May also contribute to the regulation of pancreas-specific genes and play important roles in embryonic development.

> Gene Ontology
 
Biological Process GO:0006352 DNA-templated transcription, initiation
GO:0006367 transcription initiation from RNA polymerase II promoter
GO:0008202 steroid metabolic process
GO:0008206 bile acid metabolic process
GO:0009755 hormone-mediated signaling pathway
GO:0019058 viral life cycle
GO:0019079 viral genome replication
GO:0030522 intracellular receptor signaling pathway
GO:0031016 pancreas development
GO:0042632 cholesterol homeostasis
GO:0043401 steroid hormone mediated signaling pathway
GO:0043900 regulation of multi-organism process
GO:0043902 positive regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0045069 regulation of viral genome replication
GO:0045070 positive regulation of viral genome replication
GO:0048524 positive regulation of viral process
GO:0048545 response to steroid hormone
GO:0050792 regulation of viral process
GO:0055088 lipid homeostasis
GO:0055092 sterol homeostasis
GO:0061113 pancreas morphogenesis
GO:0071383 cellular response to steroid hormone stimulus
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
GO:1903900 regulation of viral life cycle
GO:1903902 positive regulation of viral life cycle
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000980 RNA polymerase II distal enhancer sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001158 enhancer sequence-specific DNA binding
GO:0001159 core promoter proximal region DNA binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0003682 chromatin binding
GO:0003705 transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding
GO:0003707 steroid hormone receptor activity
GO:0004879 RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding
GO:0005543 phospholipid binding
GO:0035326 enhancer binding
GO:0098531 transcription factor activity, direct ligand regulated sequence-specific DNA binding
Cellular Component GO:0005667 transcription factor complex
GO:0044798 nuclear transcription factor complex
GO:0090575 RNA polymerase II transcription factor complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1266738: Developmental Biology
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-383280: Nuclear Receptor transcription pathway
R-HSA-186712: Regulation of beta-cell development
R-HSA-210747: Regulation of gene expression in early pancreatic precursor cells
Summary
SymbolNR5A2
Namenuclear receptor subfamily 5, group A, member 2
Aliases FTZ-F1beta; hB1F; FTZ-F1; hB1F-2; B1F2; liver receptor homolog-1; FTF; B1F; CPF; LRH1; CYP7A promoter-bindin ......
Chromosomal Location1q32.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NR5A2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolNR5A2
Namenuclear receptor subfamily 5, group A, member 2
Aliases FTZ-F1beta; hB1F; FTZ-F1; hB1F-2; B1F2; liver receptor homolog-1; FTF; B1F; CPF; LRH1; CYP7A promoter-bindin ......
Chromosomal Location1q32.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NR5A2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolNR5A2
Namenuclear receptor subfamily 5, group A, member 2
Aliases FTZ-F1beta; hB1F; FTZ-F1; hB1F-2; B1F2; liver receptor homolog-1; FTF; B1F; CPF; LRH1; CYP7A promoter-bindin ......
Chromosomal Location1q32.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NR5A2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0980.723
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0230.962
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1490.714
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.9650.0398
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.2840.373
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.5730.712
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.7080.0755
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.9590.195
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.4220.607
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0230.971
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8710.258
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2680.0567
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of NR5A2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.75.5-1.81
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.75.1-1.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.93.74.20.636
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.6013.60.279
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolNR5A2
Namenuclear receptor subfamily 5, group A, member 2
Aliases FTZ-F1beta; hB1F; FTZ-F1; hB1F-2; B1F2; liver receptor homolog-1; FTF; B1F; CPF; LRH1; CYP7A promoter-bindin ......
Chromosomal Location1q32.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NR5A2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNR5A2
Namenuclear receptor subfamily 5, group A, member 2
Aliases FTZ-F1beta; hB1F; FTZ-F1; hB1F-2; B1F2; liver receptor homolog-1; FTF; B1F; CPF; LRH1; CYP7A promoter-bindin ......
Chromosomal Location1q32.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NR5A2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NR5A2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNR5A2
Namenuclear receptor subfamily 5, group A, member 2
Aliases FTZ-F1beta; hB1F; FTZ-F1; hB1F-2; B1F2; liver receptor homolog-1; FTF; B1F; CPF; LRH1; CYP7A promoter-bindin ......
Chromosomal Location1q32.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NR5A2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNR5A2
Namenuclear receptor subfamily 5, group A, member 2
Aliases FTZ-F1beta; hB1F; FTZ-F1; hB1F-2; B1F2; liver receptor homolog-1; FTF; B1F; CPF; LRH1; CYP7A promoter-bindin ......
Chromosomal Location1q32.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NR5A2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNR5A2
Namenuclear receptor subfamily 5, group A, member 2
Aliases FTZ-F1beta; hB1F; FTZ-F1; hB1F-2; B1F2; liver receptor homolog-1; FTF; B1F; CPF; LRH1; CYP7A promoter-bindin ......
Chromosomal Location1q32.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NR5A2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNR5A2
Namenuclear receptor subfamily 5, group A, member 2
Aliases FTZ-F1beta; hB1F; FTZ-F1; hB1F-2; B1F2; liver receptor homolog-1; FTF; B1F; CPF; LRH1; CYP7A promoter-bindin ......
Chromosomal Location1q32.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NR5A2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.